Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 170

1.

Matrix vesicles induce calcification of recipient vascular smooth muscle cells through multiple signaling pathways.

Chen NX, O'Neill KD, Moe SM.

Kidney Int. 2017 Oct 9. pii: S0085-2538(17)30550-1. doi: 10.1016/j.kint.2017.07.019. [Epub ahead of print]

PMID:
29032812
2.

Healthcare outcomes in undocumented immigrants undergoing two emergency dialysis approaches
.

Sher SJ, Aftab W, Moorthi RN, Moe SM, Weaver CS, Messina FC, Martinez-Hoover NM, Anderson MD, Eadon MT.

Clin Nephrol. 2017 Oct;88(10):181-192. doi: 10.5414/CN109137.

PMID:
28818188
3.

Moving Beyond the Assumed: Improving Fistula Success Rates.

Wish JB, Moe SM.

J Am Soc Nephrol. 2017 Oct;28(10):2827-2829. doi: 10.1681/ASN.2017060663. Epub 2017 Jul 21. No abstract available.

PMID:
28733368
4.

Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.

Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB.

Kidney Int. 2017 Jul;92(1):26-36. doi: 10.1016/j.kint.2017.04.006.

5.

Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis.

Moe SM, Wetherill L, Decker BS, Lai D, Abdalla S, Long J, Vatta M, Foroud TM, Chertow GM.

Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1128-1138. doi: 10.2215/CJN.11141016. Epub 2017 Jun 19.

PMID:
28630081
6.

Renal Osteodystrophy or Kidney-Induced Osteoporosis?

Moe SM.

Curr Osteoporos Rep. 2017 Jun;15(3):194-197. doi: 10.1007/s11914-017-0364-1. Review.

PMID:
28497212
7.

Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.

Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM.

JAMA. 2017 Jan 10;317(2):156-164. doi: 10.1001/jama.2016.19468.

PMID:
28097356
8.

Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.

Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Mix TC, Moe SM, Patel UD, Silver J, Spiegel DM, Sterling L, Walsh L, Chertow GM.

JAMA. 2017 Jan 10;317(2):146-155. doi: 10.1001/jama.2016.19456.

PMID:
28097355
9.

Fractures in Patients with CKD: Time for Action.

Moe SM, Nickolas TL.

Clin J Am Soc Nephrol. 2016 Nov 7;11(11):1929-1931. Epub 2016 Oct 24. No abstract available.

10.

Calcium Homeostasis in Health and in Kidney Disease.

Moe SM.

Compr Physiol. 2016 Sep 15;6(4):1781-1800. doi: 10.1002/cphy.c150052.

PMID:
27783859
11.

Calcium as a cardiovascular toxin in CKD-MBD.

Moe SM.

Bone. 2017 Jul;100:94-99. doi: 10.1016/j.bone.2016.08.022. Epub 2016 Aug 27. Review.

PMID:
27576942
12.

Intracellular calcium increases in vascular smooth muscle cells with progression of chronic kidney disease in a rat model.

Rodenbeck SD, Zarse CA, McKenney-Drake ML, Bruning RS, Sturek M, Chen NX, Moe SM.

Nephrol Dial Transplant. 2017 Mar 1;32(3):450-458. doi: 10.1093/ndt/gfw274.

PMID:
27510531
13.

Skeletal Muscle Regeneration and Oxidative Stress Are Altered in Chronic Kidney Disease.

Avin KG, Chen NX, Organ JM, Zarse C, O'Neill K, Conway RG, Konrad RJ, Bacallao RL, Allen MR, Moe SM.

PLoS One. 2016 Aug 3;11(8):e0159411. doi: 10.1371/journal.pone.0159411. eCollection 2016.

14.

Calcitriol Suppression of Parathyroid Hormone Fails to Improve Skeletal Properties in an Animal Model of Chronic Kidney Disease.

Newman CL, Tian N, Hammond MA, Wallace JM, Brown DM, Chen NX, Moe SM, Allen MR.

Am J Nephrol. 2016;43(1):20-31. doi: 10.1159/000444423. Epub 2016 Feb 17.

15.

Subcutaneous nerve activity and mechanisms of sudden death in a rat model of chronic kidney disease.

Zhao Y, Chen NX, Shirazi JT, Shen C, Lin SF, Fishbein MC, Moe SM, Chen PS.

Heart Rhythm. 2016 May;13(5):1105-12. doi: 10.1016/j.hrthm.2015.12.040. Epub 2015 Dec 29.

16.

Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.

Parfrey PS, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Chertow GM.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):539-46. doi: 10.2215/CJN.06370615. Epub 2015 Nov 27. Review.

17.

Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.

Pun PH, Abdalla S, Block GA, Chertow GM, Correa-Rotter R, Dehmel B, Drüeke TB, Floege J, Goodman WG, Herzog CA, London GM, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Middleton JP.

Hemodial Int. 2016 Jul;20(3):421-31. doi: 10.1111/hdi.12382. Epub 2015 Nov 13.

18.

Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease.

Newman CL, Creecy A, Granke M, Nyman JS, Tian N, Hammond MA, Wallace JM, Brown DM, Chen N, Moe SM, Allen MR.

Kidney Int. 2016 Jan;89(1):95-104. doi: 10.1038/ki.2015.315. Epub 2016 Jan 4.

19.

Reduced skeletal muscle function is associated with decreased fiber cross-sectional area in the Cy/+ rat model of progressive kidney disease.

Organ JM, Srisuwananukorn A, Price P, Joll JE, Biro KC, Rupert JE, Chen NX, Avin KG, Moe SM, Allen MR.

Nephrol Dial Transplant. 2016 Feb;31(2):223-30. doi: 10.1093/ndt/gfv352. Epub 2015 Oct 5.

20.

Pathophysiology of Vascular Calcification.

Chen NX, Moe SM.

Curr Osteoporos Rep. 2015 Dec;13(6):372-80. doi: 10.1007/s11914-015-0293-9. Review.

PMID:
26409849

Supplemental Content

Loading ...
Support Center